Literature DB >> 17944994

Carboxypeptidase U (TAFIa) activity is induced in vivo in ischemic stroke patients receiving thrombolytic therapy.

J L Willemse, R Brouns, E Heylen, P P De Deyn, D F Hendriks.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17944994     DOI： 10.1111/j.1538-7836.2007.02798.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  6 in total

1.  Prolyl carboxypeptidase activity decline correlates with severity and short-term outcome in acute ischemic stroke.

Authors:  Kaat Kehoe; Raf Brouns; Robert Verkerk; Sebastiaan Engelborghs; Peter Paul De Deyn; Dirk Hendriks; Ingrid De Meester
Journal:  Neurochem Res       Date:  2014-11-05       Impact factor: 3.996

2.  Thrombin-activatable fibrinolysis inhibitor is activated in vivo in a baboon model of Escherichia coli induced sepsis.

Authors:  Paul Y Kim; Paula Y G Kim; Fletcher B Taylor; Michael E Nesheim
Journal:  J Thromb Thrombolysis       Date:  2012-05       Impact factor: 2.300

Review 3.  Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy?

Authors:  J L Willemse; E Heylen; M E Nesheim; D F Hendriks
Journal:  J Thromb Haemost       Date:  2009-08-28       Impact factor: 5.824

4.  Activated thrombin-activatable fibrinolysis inhibitor is generated in vivo at levels that can substantially affect fibrinolysis in chimpanzees in response to thrombin generation.

Authors:  P Y G Kim; P Y Kim; H Hoogendorn; A R Giles; M E Nesheim
Journal:  J Thromb Haemost       Date:  2008-07-04       Impact factor: 5.824

Review 5.  Carboxypeptidase U (CPU, TAFIa, CPB2) in Thromboembolic Disease: What Do We Know Three Decades after Its Discovery?

Authors:  Karen Claesen; Joachim C Mertens; Dorien Leenaerts; Dirk Hendriks
Journal:  Int J Mol Sci       Date:  2021-01-17       Impact factor: 5.923

6.  Neurogranin and tau in cerebrospinal fluid and plasma of patients with acute ischemic stroke.

Authors:  Ann De Vos; Maria Bjerke; Raf Brouns; Naomi De Roeck; Dirk Jacobs; Lien Van den Abbeele; Kaat Guldolf; Henrik Zetterberg; Kaj Blennow; Sebastiaan Engelborghs; Eugeen Vanmechelen
Journal:  BMC Neurol       Date:  2017-08-30       Impact factor: 2.474
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.